ImmuDyn immune modulatory lipid preparation data

DYGN announced preliminary results from a Phase I/II trial that began last fall in India. Patients with ITP received weekly intramuscular injections of 0.5 mg ImmuDyn for 9 weeks. Of the 13 patients enrolled, 11 showed moderate to substantial increases in platelet counts, and the other 2 are still being followed. No safety issues were raised. Complete results will be presented in September at the International Society of Hematology in Stockholm. ...